TopFunds

Gilead Sciences, Inc.

NASDAQ: GILD

Stock price

156.19 USD

(+0%) TODAY

Drug Manufacturers - General
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
11.9
9.9
3.5
4.2
4.2
0.1
4.9
3.6
4.5
0.4
6.8
(5.5)%
02Free cash flow per share
13.5
12
8.6
5.7
6.5
6
8.6
6.6
5.9
8.2
7.5
(5.7)%
03Dividends per share
1.3
1.8
2.1
2.3
2.5
2.7
2.8
2.9
3
3.1
3.2
9.4%
04Dividends payout, %
10.4%
18.2%
59%
54.5%
59.8%
28%
57.9%
80.8%
67.2%
8.2%
47%
16.4%
PROFIT AND LOSS STATEMENT
05Revenue
32,639
30,390
26,107
22,127
22,449
24,689
27,305
27,281
27,116
28,754
29,442
(1)%
06% Change
-
-
-
-
-
-
-
-
-
-
-
(1)%
07Cost of revenue
(4,006)
(4,261)
(4,371)
(4,853)
(4,675)
(4,572)
(6,601)
(5,657)
(6,498)
(6,251)
(6,234)
4.5%
08Gross profit
28,633
26,129
21,736
17,274
17,774
20,117
20,704
21,624
20,618
22,503
23,208
(2.1)%
09% Margin
87.7%
86%
83.3%
78.1%
79.2%
81.5%
75.8%
79.3%
76%
78.3%
78.8%
80.4% A
10Operating expenses
(6,440)
(8,496)
(7,612)
(7,976)
(8,436)
(16,046)
(10,786)
(14,294)
(13,013)
(20,841)
(11,507)
6%
11% of Revenue
(19.7)%
(28)%
(29.2)%
(36.1)%
(37.6)%
(65)%
(39.5)%
(52.4)%
(48)%
(72.5)%
(39.1)%
(42.5)% A
12Operating Income
22,193
17,633
14,124
8,200
4,287
4,071
9,918
7,330
7,605
1,662
11,701
(6.2)%
13Income tax expense
(3,553)
(3,609)
(8,885)
(2,339)
(204)
(1,580)
(2,077)
(1,248)
(1,247)
(211)
(1,286)
(9.7)%
14Net Income
18,108
13,501
4,628
5,455
5,386
123
6,225
4,592
5,665
480
8,510
(7.3)%
15% Margin
55.5%
44.4%
17.7%
24.7%
24%
0.5%
22.8%
16.8%
20.9%
1.7%
28.9%
23.4% A
16Shares Outstanding
1,521
1,358
1,319
1,308
1,277
1,263
1,262
1,262
1,258
1,255
1,255
(1.9)%
17EPS Basic
12.4
10.1
3.5
4.2
4.2
0.1
5
3.7
4.5
0.4
6.8
(5.8)%
18EPS Diluted
11.9
9.9
3.5
4.2
4.2
0.1
4.9
3.6
4.5
0.4
6.8
(5.5)%
19EBITDA
23,445
19,219
15,933
10,305
7,559
4,133
11,329
8,852
10,496
4,434
13,580
(5.3)%
% Margin
71.8%
63.2%
61%
46.6%
33.7%
16.7%
41.5%
32.5%
38.7%
15.4%
46.1%
42.5% A
20Net Interest Income (expense)
(688)
(964)
(1,118)
(1,077)
(995)
(984)
(1,001)
(829)
(568)
(696)
(675)
(0.2)%
21Net Debt / EBITDA
0.4
0.9
1.6
0.9
1.7
6.1
1.9
2.2
1.8
3.8
1.3
2.1 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
12,851
8,229
7,588
17,940
11,631
5,997
5,338
5,412
6,085
9,991
7,564
(5.2)%
23Short-term investments
1,756
3,666
17,922
12,149
12,721
1,411
1,182
973
1,179
1,577
2,049
1.6%
24Accounts receivable
5,854
4,514
3,851
3,327
3,582
4,892
4,493
4,777
4,660
4,420
4,913
(1.7)%
25Other current assets
2,346
1,592
1,661
1,606
1,440
2,013
2,141
1,774
2,374
1,475
2,042
(1.4)%
26Inventory
1,955
1,587
801
814
922
1,683
1,618
1,507
1,787
1,710
1,774
(1)%
27Total Current Assets
24,762
19,588
31,823
35,836
30,296
15,996
14,772
14,443
16,085
19,173
18,342
(3)%
Non-Current Assets
28Net property, plant & equipment
2,276
2,865
3,295
4,006
4,502
4,967
5,121
5,475
5,317
5,414
5,606
9.4%
29Long-term investments
11,601
20,485
11,184
1,423
1,488
502
1,309
1,245
1,163
-
2,974
(12.7)%
30Other non-current assets
13,077
14,039
23,981
22,410
25,341
46,942
46,750
42,007
39,560
34,409
32,101
9.4%
31Total Non-Current Assets
26,954
37,389
38,460
27,839
31,331
52,411
53,180
48,727
46,040
39,823
40,681
4.2%
Total Assets
51,716
56,977
70,283
63,675
61,627
68,407
67,952
63,171
62,125
58,995
59,023
1.3%
LIABILITIES
Current Liabilities
32Accounts payable
1,178
1,206
814
790
713
844
705
905
550
833
715
(4.9)%
33Short-term debt
982
-
2,747
2,748
2,499
2,757
1,516
2,273
1,798
1,815
2,807
11.1%
34Other current liabilities
7,730
8,012
8,074
7,067
6,547
7,796
9,389
8,060
8,932
9,356
8,291
0.7%
35Total Current Liabilities
9,890
9,218
11,635
10,605
9,759
11,397
11,610
11,238
11,280
12,004
11,813
1.8%
Non-Current Liabilities
36Long-term debt
21,073
26,346
30,795
24,574
22,094
28,645
25,179
22,957
23,189
24,896
22,129
0.5%
37Other non-current liabilities
1,640
2,050
7,352
6,962
7,124
10,144
10,099
7,767
4,907
2,849
2,463
4.2%
38Total Non-Current Liabilities
22,713
28,396
38,147
31,536
29,218
38,789
35,278
30,724
28,096
27,745
24,592
0.8%
39Total Liabilities
32,603
37,614
49,782
42,141
38,977
50,186
46,888
41,962
39,376
39,749
36,405
1.1%
SHAREHOLDERS` EQUITY
40Common stock
1
1
1
1
1
1
1
1
1
1
1
-
41Retained earnings / (deficit)
18,001
18,154
19,012
19,024
19,388
14,381
16,324
15,687
16,304
11,497
13,730
(2.7)%
42Accumulated other comprehensive income / (loss)
88
278
165
80
85
(60)
83
2
28
132
39
(7.8)%
43Noncontrolling interests
579
476
59
147
125
19
(5)
(31)
(84)
(84)
(84)
-
44Total shareholders' equity
19,113
19,363
20,501
21,534
22,650
18,221
21,064
21,209
22,749
19,246
22,618
1.7%
45Total Liabilities and shareholders' Equity
51,716
56,977
70,283
63,675
61,627
68,407
67,952
63,171
62,125
58,995
59,023
1.3%
46Total Debt
22,055
26,346
33,542
27,322
24,593
31,402
26,695
25,230
24,987
26,711
24,936
1.2%
47Net Debt
9,204
18,117
25,954
9,382
12,962
25,405
21,357
19,818
18,902
16,720
17,372
6.6%
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
18,108
13,501
4,628
5,455
5,386
123
6,225
4,592
5,665
480
8,510
(7.3)%
49Depreciation & amortization
1,098
1,158
1,286
1,429
1,404
1,480
2,050
2,103
2,693
2,767
2,760
9.7%
50Share-based compensation expense
382
380
638
845
636
643
635
644
766
835
894
8.9%
51Changes in working capital and other assets
1,662
2,008
5,346
671
1,718
5,922
2,474
1,733
(1,118)
6,746
(2,145)
-
52Net cash flows from operating activities
21,250
17,047
11,898
8,400
9,144
8,168
11,384
9,072
8,006
10,828
10,019
(7.2)%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(747)
(748)
(590)
(924)
(825)
(650)
(579)
(728)
(585)
(523)
(563)
(2.8)%
54Purchases of investments / marketable securities
(17,239)
(25,976)
(23,314)
(10,389)
(32,228)
(20,770)
(3,897)
(1,942)
(2,372)
(736)
(4,072)
(13.4)%
55Proceeds from maturities of marketable securities
5,511
14,739
18,261
25,858
29,921
32,718
2,910
2,002
1,844
2,592
909
(16.5)%
56Other investing activities
-
-
(10,426)
(190)
(4,685)
(25,913)
(1,565)
(1,798)
(1,152)
(4,782)
(1,067)
-
57Net cash flows from investing activities
(12,475)
(11,985)
(16,069)
14,355
(7,817)
(14,615)
(3,131)
(2,466)
(2,265)
(3,449)
(4,793)
(9.1)%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
(9,683)
(10,793)
(720)
(2,611)
(1,540)
(1,327)
(377)
(1,087)
(768)
(728)
(1,514)
(16.9)%
59Dividends paid, net
(1,874)
(2,455)
(2,731)
(2,971)
(3,222)
(3,449)
(3,605)
(3,709)
(3,809)
(3,918)
(4,003)
7.9%
60Debt issuance (repayments), net
9,689
4,268
7,174
(6,250)
(2,750)
5,684
(4,750)
(1,500)
(270)
1,494
(1,788)
-
61Other financing activities
(4,016)
(745)
(330)
(486)
(122)
(138)
(145)
(173)
(278)
(281)
(440)
(19.8)%
62Net cash flows from financing activities
(5,884)
(9,725)
3,393
(12,318)
(7,634)
770
(8,877)
(6,469)
(5,125)
(3,433)
(7,745)
2.8%
63Increase (decrease) in cash and cash equivalents
2,824
(4,622)
(641)
10,352
(6,309)
(5,634)
(659)
74
673
3,906
(2,427)
-
64Cash and equivalents, ending balance
12,851
8,229
7,588
17,940
11,631
5,997
5,338
5,412
6,085
9,991
7,564
(5.2)%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
20,503
16,299
11,308
7,476
8,319
7,518
10,805
8,344
7,421
10,305
9,456
(7.5)%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Gilead Sciences, Inc. (GILD) financial statements and performance

Explore Gilead Sciences, Inc. (GILD) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.